R&D channel feed – Endpoints News

R&D channel feed

Arena takes a big step down the comeback trail with PhII success, shares rocket up

8 years ago

FDA orders a rare retreat on Amicus’ migalastat, dropping PhIII demand and signaling a major shift for drug developers

8 years ago

Pioneering gene therapy patients stay on track, boosting Spark’s hemophilia B program

8 years ago

Alnylam, Sanofi flag another promising step forward for PhIII hemophilia drug

8 years ago

FDA raises big safety issues in Novartis’ CAR-T review, but spotlights post-marketing path forward

8 years ago

Inotek shares crater (again) as another glaucoma drug study flops

8 years ago

Troubled by deaths, FDA orders Merck to slam the brakes on three Keytruda studies

8 years ago

Personalized cancer vaccines stake their claim to the next frontier in immuno-oncology

8 years ago

Bristol-Myers’ tarnished checkpoint star Opdivo beats out Yervoy in surprise PhIII

8 years ago

Far from the big hubs, Apellis is steering its rival to Alexion's Soliris into a PhIII program

8 years ago

Alkermes claims a success in PhIII schizophrenia head-to-head, but where’s the benefit for patients?

8 years ago

Cara tries hard to spin the data, but key PhIIb pain study fails and shares slide south

8 years ago

Investors — and AstraZeneca CEO Pascal Soriot — are getting a tad nervous as MYSTIC data loom

8 years ago

Coherus restructures, axes 51 staffers in wake of an FDA rejection of its knockoff of Amgen’s Neulasta

8 years ago

Hammered on a gene therapy setback, Dimension cuts staff and circles the wagons

8 years ago

Pfizer preps new hires as it begins building a $200M R&D campus

8 years ago

Teva and Xenon rack up another setback as PhIIb study fails on every endpoint

8 years ago

In a stunner, Merck lands positive PhIII for its CETP outcast anacetrapib

8 years ago

Little Alder bags positive PhIII migraine data, but giant rivals are racing ahead in a crowded field

8 years ago

Alnylam makes a bull case for PhIII-ready porphyria drug, but shares sink anyway

8 years ago

Neothetics ponders the future after sole therapy proves an ugly flop in PhII, eviscerating shares

8 years ago

Matinas Bio shares are crushed on disappointing PhII antifungal data

8 years ago

Seattle Genetics gets a PhIII win for Adcetris, but shares slide as frets linger

8 years ago

Roche’s hemophilia drug slashes bleeding rate, boosting blockbuster projections — but doubts on safety linger

8 years ago

First page Previous page 295 296 297298299 300 301 Next page Last page